Prevalence of high-risk human papillomavirus and cervical intraepithelial neoplasias in a previously unscreened population - A pooled analysis from three studies

International Journal of Cancer

Volumn 132, Issue 7, 2013, Pages 1693-1699

  Basu, Partha ^a   Mittal, Srabani ^b   Bhaumik, Suchismita ^c   Mandal, Shyam Sunder ^a   Samaddar, Anusree ^a   Ray, Chinmayi ^d   Siddiqi, Maqsood ^c   Biswas, Jaydip ^a   Sankaranarayanan, Rengaswamy ^e  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b Child in Need Institute   (India)

^c Cancer Foundation of India   (India)

^d VIVEKANANDA INSTITUTE OF MEDICAL SCIENCES   (India)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

cervical intraepithelial neoplasia; high risk human papillomavirus; hybrid capture 2; population prevalence; unscreened population

Indexed keywords

ACETIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INVASION; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EDUCATION; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MARRIAGE; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RECTUM BIOPSY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CROSS-SECTIONAL STUDIES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INDIA; MASS SCREENING; META-ANALYSIS AS TOPIC; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROGNOSIS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84873096490     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27793     Document Type: Article

References (31)

1. Ferlay J, Bray F, Pisani P, et al. International Agency for Research on Cancer (IARC). GLOBOCAN2002: cancer. Incidence, mortality and prevalence worldwide. Lyon, France: IARC Press, 2004, Cancer Base No. 5, version 2.0.
2. Wright TC, Jr,. Cervical cancer screening in the 21st century: is it time to retire the PAP Smear? Clin Obstet Gynecol 2007; 50: 313-23.
3. Bhatla N, Singla S, Awasthi D,. Human papillomavirus deoxyribonucleic acid testing in developed countries. Best Pract Res Clin Obstet Gynaecol 2012; 26: 209-20.
4. Basu PS, Sankaranarayanan R, Mandal R, et al.; Calcutta Cervical Cancer Early Detection Group. Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India. Int J Gynecol Cancer 2003; 13: 626-32.
5. Sankaranarayanan R, Basu P, Wesley RS, et al. Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa. Int J Cancer 2004; 110: 907-13.
6. Sankaranarayanan R, Chatterji R, Shastri SS, et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicentre study in India. Int J Cancer 2004; 112: 341-47.
7. Sankaranarayanan R, Wesley RS,. A practical manual on visual screening for cervical neoplasia. IARC technical publication no. 41. Lyon: International Agency for Research on Cancer, 2003.
8. Mayrand M, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
9. Ahmad OB, Boschi-Pinto C, Lopez AD, et al. Age standardization of rates: a new WHO standard. GPE discussion paper series: No.31 EIP/GPE/EBD. World Health Organization, Geneva, 2001.
10. Franceschi S, Rajkumar R, Snijders PJ, et al. Papillomavirus infection in rural women in southern India. Br J Cancer 2005; 92: 601-6.
11. Murthy NS, Mathew A,. Cancer epidemiology, prevention and control. Curr Sci 2004; 86: 518-27.
12. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
13. Bosch FX, de Sanjose S,. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3-13.
14. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004; 90: 638-45.
15. Wall SR, Scherf CF, Morison L, et al. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 2005; 93: 1068-76.
16. Ting J, Kruzikas DT, Smith JS,. A global review of age-specific and overall prevalence of cervical lesions. Int J Gynecol Cancer 2010; 20: 1244-49.
17. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
18. Cox JT, Schiffman M, Solomon D,. ASCUS-low-grade squamous intraepithelial lesion Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 1406-12.
19. Stoler MH, Schiffman M,. Inter-observer reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500-5.
20. Castle PE, Stoler MH, Solomon D, et al. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 2007; 127: 805-15.
21. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113: 18-25.
22. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women diagnosed with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-34.
23. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-53.
24. Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106: 396-403.
25. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360: 228-9.
26. Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 2002; 102: 519-25.
27. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 283: 87-93.
28. Castle PE, Schiffman M, Wheeler CM,. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol 2004; 191: 1590-7.
29. Basu P, Sarkar S, Mukherjee S, et al. Women's perceptions and social barriers determine compliance to cervical screening: results from a population based study in India. Cancer Detect Prev 2006; 30: 369-74.
30. Belinson J, Qiao YL, Pretorius R, et al. Shanxi province cervical cancer screening studies: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 439-44.
31. Snijders PJ, van den Brule AJ, Meijer CJ,. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1-6.